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Abstract
Background: We explore the use of a clinical orthovoltage X-ray treatment unit as a small-animal
radiation therapy system in a tumoral model of cervical cancer.
Methods: Nude mice were subcutaneously inoculated with 5 × 106 HeLa cells in both lower limbs.
When tumor volume approximated 200 mm3 treatment was initiated. Animals received four 2 mg/
kg intraperitoneal cycles (1/week) of cisplatin and/or 6.25 mg/kg of gemcitabine, concomitant with
radiotherapy. Tumors were exposed to 2.5 Gy/day nominal surface doses (20 days) of 150 kV X-
rays. Lead collimators with circular apertures (0.5 to 1.5 cm diameter) were manufactured and
mounted on the applicator cone to restrict the X-ray beam onto tumors. X-ray penetration and
conformality were evaluated by measuring dose at the surface and behind the tumor lobe by using
HS GafChromic film. Relative changes in tumor volume (RTV) and a clonogenic assay were used to
evaluate the therapeutic response of the tumor, and relative weight loss was used to assess toxicity
of the treatments.
Results: No measurable dose was delivered outside of the collimator apertures. The analysis
suggests that dose inhomogeneities in the tumor reach up to ± 11.5% around the mean tumor dose
value, which was estimated as 2.2 Gy/day. Evaluation of the RTV showed a significant reduction of
the tumor volume as consequence of the chemoradiotherapy treatment; results also show that
toxicity was well tolerated by the animals.
Conclusion: Results and procedures described in the present work have shown the usefulness
and convenience of the orthovoltage X-ray system for animal model radiotherapy protocols.
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Background
Small animal models of human cancer have been used
around the world to develop and evaluate several treat-
ments schemes in cancer research [1]. Radiation treat-
ments have been applied in different animal tumor
models to evaluate and validate potential treatments in
humans [2-4]. However, the absence of a dedicated small-
animal irradiator, explicit for radiation treatments, has led
to the use of clinical devices such as 60Co irradiators,
linacs, brachytherapy sources, etc., that normally do not
conform doses to a target volume in small animals, and
also are cumbersome to manipulate in experiments. In
addition, systemic secondary effects related with noncon-
formal irradiations, such as immune response, bone mar-
row depletion, etc., may mask the effect of interest in
tumor, or in the evaluation of chemotherapy agents com-
bined with radiotherapy.
Recently, research groups have been working in the devel-
opment of dedicated small-animal irradiation systems
that potentially will delivery conformal doses to specifi-
cally chosen targets, either tumors or normal tissues [5-8].
However, these systems are still in the process of proto-
type design or in validation studies, and their availability
and cost will possibly limit the access to this technology.
This might be particularly important in small research
centers or developing countries, not able to afford the
acquisition of a small animal irradiator immediately.
In this report, we explore the potential use of a clinical
orthovoltage X-ray treatment unit as a small-animal radi-
ation system. These kinds of units are available in several
hospitals and medical centers, and their easy manipula-
tion and accessibility, as compared with linacs and 60Co
units, could turn them into an important tool for radia-
tion therapy experiments with small animals.
To demonstrate the usefulness of this system in radiation
therapy experiments, in the present work, a tumor model
of cervical cancer was developed in nude mice and treated
with concurrent chemoradiotherapy based on cisplatin.
Our group is interested in the evaluation of chemoradio-
therapy protocols for cervical cancer based on cisplatin,
gemcitabine and different radiosensitizers. Cisplatin has
been considered the most active cytotoxic agent for treat-
ment of squamous carcinoma of the cervix, and is com-
monly used in the clinical practice in combination with
radiation treatments [9-11]. Gemcitabine has shown very
potent radiosensitizing properties in cervical cancer and is
widely used in concurrent chemoradiotherapy with cispl-
atin [9,12]. Simultaneous administration of chemother-
apy and radiotherapy which act upon different phases of
the cell cycle may provide synergestic tumor response
[13,14], but there are still questions with respect to this
hypothesis. For this reason, preclinical evaluations of dif-
ferent treatments schemes based on chemoradiotherapy
procedures need to be performed in tumor animal mod-
els. The results and methodology described in this work
have shown the feasibility for the use of an orthovoltage
X-ray system in chemoradiotherapy research protocols in
tumor models.
Methods
Orthovoltage X-ray system specifications
The orthovoltage X-ray treatment unit used in this experi-
ment (D3225, Gulmay Medical Ltd., UK) (Figure 1) uses
a metal ceramic X-ray tube capable of delivering X-rays at
voltages from 20 to 220 kV. The unit has several applicator
cones (with different length and openings) that define
treatment distances and field sizes. The anatomical
dimensions in the present study have led us to choose 150
kV, 10 mA, added filtration of 2.25 mm Al and 0.15 mm
Cu, and a treatment distance (source-to-surface distance,
SSD) equal to 20 cm and a 2 cm diameter circular field
size. Under these conditions the effective energy of the X-
ray beam was measured to be Eeff = 60.9 keV (Half Value
Layer, HVL = 0.47 mm Cu) [15,16] and the absorbed dose
rate to water at SSD was 2.16 Gy/min. Dose rate measure-
ments were performed by the Medical Physics personnel
from the Radiotherapy Department at Instituto Nacional
de Cancerología (INCan) using a calibrated end-window
parallel-plate ionization chamber (Marcus Advance, PTW,
Germany).
Tumor model
All animal procedures reported in the present paper were
performed according to the NIH Animal Use and Care
Guidelines (USA) and were approved by the INCan Ethics
Committee. Female athymic Balb C nu/nu mice (6–8
weeks of age) used in this experiment were obtained from
the Instituto Nacional de Nutrición (INNSZ), Mexico
City, and were kept in a pathogen-free environment and
fed  ad libitum. The established, transplantable, HeLa
human cervical cancer cell line was obtained from ATCC
(Rockville, Maryland, USA) and was routinely maintained
as a monolayer in Dubelcco's modified Eagles's medium
(DMEM) with 10% fetal calf serum (FCS) (Gibco, BRL,
Gaithersburg, MD, USA), and incubated in a 5% CO2
atmosphere and high humidity. Cells were harvested with
0.025% trypsin (Sigma-Aldrich Co., St. Louis, MO, USA)
and 1 mM EDTA (Gibco, BRL). Animals were inoculated
subcutaneously with 5 × 106 HeLa cells, suspended in
DMEM without FCS, in both lower limbs. The limbs were
selected as the site for tumor growth (Figure 2) to mini-
mize irradiation to other body organs. After inoculation,
tumors were measured, weekly, in two perpendicular
diameters using a caliper and the tumor volume was
determined by using the following relation:
V = π/6 × (large diameter × [short diameter]2) [17,18].Journal of Experimental & Clinical Cancer Research 2008, 27:57 http://www.jeccr.com/content/27/1/57
Page 3 of 11
(page number not for citation purposes)
When tumor volume approximated 200 mm3 the animals
were pair-matched into treatments and control groups
and the treatments were initiated.
Conformal X-ray beam design and evaluation
To perform a conformal irradiation that will cover just the
tumoral volume (typically 200 mm3 grown in a mouse
lower limb), lead collimators (2 mm thick) with 0.5 to 1.5
cm circular diameter apertures were manufactured (Figure
3) and mounted on the applicator cone to restrict the X-
ray beam onto the tumor lobe. The thickness of the colli-
mators was adequate to guarantee minimal penetration
and dispersion of the X-ray beam outside of the collima-
tor's aperture. The HVL for 60 keV photons in lead is 1.2
× 10-3 mm [19]. X-ray penetration and conformal irradia-
tion was evaluated by measuring dose at the surface
(entrance dose) and behind the tumor lobe (exit dose)
(Figure 4). HS GafChromic film was used to estimate the
delivered dose.
GafChromic irradiation and readout
Gafchromic films have been designed for use with
gamma, x-ray and charged particles and can be used to
measure and map radiation fields of a wide range of ener-
gies down to 5 keV [20,21]. When the film is exposed to
ionizing radiation, a polymerization reaction in the film
active layer is initiated resulting in the production of a
blue-colored dye-polymer, and the amount of the color
change is proportional to the dose absorbed by the active
layer.
The GafChromic film (HS type) response as a function of
dose (from 0 to 5 Gy) was measured using the same X-ray
treatment unit; under the same conditions of tumor irra-
diations. This curve was used as a calibration to interpret
the HS film response (i.e. the change in color).
Readout of HS GafChromic film followed a procedure
previously described [22]. Briefly, film response was digi-
tized 48 h after the end of irradiations with a Microtek
ScanMarker 8700 scanner (Microtek Lab. Inc., USA) in
transmission mode, using 36 bits RGB (12 bits per color),
and saved as tagged image file format. The optical density
range of the scanner was set to a maximum with all filters
and image enhancement options turned off. The scanning
resolution used was 300 dpi. Every film was scanned using
a) Orthovoltage X-ray unit (Gulmay D3225) Figure 1
a) Orthovoltage X-ray unit (Gulmay D3225); b) filters and applicator cones.Journal of Experimental & Clinical Cancer Research 2008, 27:57 http://www.jeccr.com/content/27/1/57
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an opaque frame to minimize light contributions from
areas other than the film. Images were analyzed using the
ImageJ (Version 1.36b) software (Wayne Rasband, NIH,
USA). The film response, R, was quantified as:
where Cni and Ci are the measured color levels of the back-
ground (non irradiated) and irradiated films, respectively.
Chemotherapy
Both cisplatin (Sigma-Aldrich Co., St Louis MO, USA) and
gemcitabine (Eli Lilly and Co, USA) were reconstituted
with sterile 0.9% saline in a laminar air-flow hood under
sterile condition. Animals received four intraperitoneal
cycles (1 cycle/week, on Mondays) of 2 mg/kg of cisplatin
and/or 6.25 mg/kg of gemcitabine, concomitant with
radiotherapy. Doses of both chemotherapeutic agents
were adjusted from recommended doses used in the treat-
ment of cervical carcinoma in humans (cisplatin: 40 mg/
m2, gemcitabine: 125 mg/m2) [9] and the mass and body
surface of mice and human adult females [23].
Radiotherapy
Tumors were exposed to nominal 2.5 Gy entrance doses,
5 days/week, to complete 50 Gy. The dose and the sched-
ule were selected because of their similarity to clinical
patient treatment [9]. Tumor dose was estimated from
average entrance and exit doses (measured with the HS
film) taking into account the particular collimator used
during the treatment. During irradiation, mice were
anaesthetized with 1–3% isoflurane in 100% oxygen
using an animal anesthesia inhalation unit (Bickford,
Wales Center, NY). The X-ray beam was centered on the
tumor lobe by using one of the different lead collimators,
according with the tumor size at the moment of irradia-
tion.
Treatments groups
Animals which developed tumors in both extremities
were randomized into three groups maintaining a similar
tumor size distribution. Group A (n = 24 tumor lobes, i.e.
12 mice): treated with radiotherapy, cisplatin and gemcit-
abine as explained above; Group B (n = 26 tumor lobes):
treated with radiotherapy and gemcitabine; Group C (n =
12 tumor lobes): untreated controls. Tumor volumes were
measured as described, and a relative tumor volume
(RTV) was determined using the relation: RTV = Vi/V0,
where Vi is the weekly-measured tumor volume and V0 is
the initial tumor volume (at the beginning of the treat-
ment). The weight of each mouse was documented at each
measurement to evaluate the toxicity of treatments.
Clonogenic assay
Two weeks after the end of treatments, mice were sacri-
ficed under isoflurane anesthesia and the tumors visibly
present at the limbs were removed, washed in PBS and
sectioned with surgical blade in sterile conditions. A mir-
ror representative fragment was histologically analyzed
with hematoxilin and eosin stain, to corroborate the pres-
ence of viable tissue, and the other fragment was used for
clonogenic assay. The clonogenic in vitro assay was per-
formed according the method described by Munshi A, et
al [24] with modifications. The experiments were done by
duplicate. Necrotic tissue was removed from the fragment,
and isolated cells were obtained by mechanical fragmen-
tation of the tumoral tissue and prepared into a single cell
suspension by typsinization (PBS-EDTA 10 mM, pH 7.4,
trypsin 0.2% (w/v)), 30 min 37°C with constant agita-
tion. The cell number was obtained using blue trypan in a
hemocytometer. A number of 5 × 104 cells were plated in
Petri dishes containing high glucose-Dulbecco's modified
Eagle's medium (DMEM, Gibco) supplemented with 10%
bovine fetal serum (Gibco), 300 U/ml penicillin and 0.3
RL o g
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Tumor xenograft of cervical cancer developed by subcutane- ous injection of 5 × 106 HeLa cells at the lower limbs of nude  mice Figure 2
Tumor xenograft of cervical cancer developed by 
subcutaneous injection of 5 × 106 HeLa cells at the 
lower limbs of nude mice. Arrows indicate the tumor 
lobes.Journal of Experimental & Clinical Cancer Research 2008, 27:57 http://www.jeccr.com/content/27/1/57
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mg/ml streptomycin (Sigma). The cellular colonies were
fixed with buffered formaldehyde (10.0% v/v), and
stained with crystal violet (0.5% w/v). Proportion of clo-
nogenic cells was determined by counting colonies 15 day
later.
Statistical analysis
Values are reported as mean ± SEM (standard error of the
mean). Statistical analysis was performed using one-way
analysis of variance (ANOVA) to compare the relative
tumor volume and weight using SPSS Base 12.0 software
Lead collimators with different diameters (0.5, 1.0, 1.5 cm) and a thickness of 2 mm, used to restrict the X-ray beam onto the  tumor lobes Figure 3
Lead collimators with different diameters (0.5, 1.0, 1.5 cm) and a thickness of 2 mm, used to restrict the X-ray 
beam onto the tumor lobes.
Experimental setup to evaluate the entrance and exit dose in the tumor lobe, using HS Gafchromic film Figure 4
Experimental setup to evaluate the entrance and exit dose in the tumor lobe, using HS Gafchromic film.Journal of Experimental & Clinical Cancer Research 2008, 27:57 http://www.jeccr.com/content/27/1/57
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(SPSS Inc, Chicago, IL). Differences were statistically com-
pared using between-groups multiple comparisons. When
necessary, comparisons among means were Bonferroni
adjusted. A value of p <0.05 was defined as an acceptable
probability for a significant difference between means.
Statistical power of the ANOVA was calculated with a sig-
nificant level of α = 0.05. A value lower than 0.5 was con-
sidered an insufficient power of the design for a medium
size effect.
Results
Figure 5 shows photographs of irradiated HS GafChromic
film used to estimate the uniformity of the delivered dose
when the lead collimators were used. Analysis of the
images shows that no measurable dose was delivered out-
side of the circular aperture of the collimators.
In Figure 6, the film calibration curve is presented. This
figure shows the linear response of the red, green and blue
components (RGB mode) as function of the dose in the
measured interval. The red component was used in the
analysis because of its higher sensitivity.
Table 1 show the measured entrance and exit doses when
different collimators were used. Exposed HS films were
scanned as described previously, and the image analysis
was performed by drawing 3 to 5 regions of interest (ROI),
of the same dimensions, in several positions around the
central exposed area. No inhomogeneities in the response
larger than 5% were observed across the films. An average
value of the response in the ROIs was used to estimate the
dose in each film by means of the calibration curve. In
Table 1, results from all measured entrance doses are con-
sistent with the nominal 2.5 Gy. No statistically signifi-
cant differences among collimators are observed in the
measured entrance or exit doses. The differences between
the entrance and exit doses are consequence of the X-ray
attenuation in the limb bone, tumoral and muscle tissues.
Figure 7 shows the relative tumor volume vs. time (i.e.
therapeutic response) for the control and the experimen-
tal groups. The plot shows that the tumor lobe increases
continuously in the control while practically disappears in
the experimental groups. There was not difference in the
therapeutic response between both experimental groups.
In Table 2, the number of colonies measured in the clono-
genic assay is reported. The results show that no colonies
were formed after the treatment with radiation and chem-
otherapy. These results was not due to necrosis or not via-
ble cells, because the histological examination confirms
the presence of macroscopic residual tumoral cells in
almost the whole tissue samples employed in the clono-
genic assay, although in some animals of groups A and B
there was no evidence of neoplastic cells (8/16), in com-
parison with the control group (100%).
Finally, Figure 8 shows the relative weight along the exper-
iment time. The controls do not lose weight, they show an
initial increase of around 8%, and afterwards the weight
remained constant. In Groups A and B the loss of weight
is evident after two weeks of treatment and becomes more
pronounced for Group A, afterwards. Two weeks after the
end of treatment, animals tend to recover their original
weight. It is evident that the chemoradiotherapy treat-
ment with cisplatin (Group A) results in a more signifi-
cant loss of weight during the period of treatment, thus a
higher toxicity of this treatment modality.
Discussion
Previous published works of radiotherapy procedures in
tumor models have reported the use of linacs, Co-60 and
Digitized images of HS Gafchromic film exposed to nominal 2.5 Gy, using collimators C1, C2 and C3 (see Figure 3) Figure 5
Digitized images of HS Gafchromic film exposed to nominal 2.5 Gy, using collimators C1, C2 and C3 (see 
Figure3).Journal of Experimental & Clinical Cancer Research 2008, 27:57 http://www.jeccr.com/content/27/1/57
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Cs-137 irradiators, or brachytherapy sources [5-8], which
in the real experimental practice are difficult to operate
with small animals. A main goal in this work has been to
report that, while new dedicated radiotherapy systems for
small animals are in the process of development and eval-
uation, clinical orthovoltage x-ray units can be used in
radiotherapy experiments with tumor models.
The use of orthovoltage x-rays units has been more com-
mon in clinical veterinary therapy in pets (cats and dogs)
[25] than in research procedures with tumor models in
rodents, probably because the energies and range of the
orthovoltage X-rays. Orthovoltage treatment units can
produce X-ray beams with voltages in the range of 150 to
500 kV. At these energies, the maximum radiation dose
occurs close to the skin, with 90% of that value occurring
Calibration curve (Response vs. Dose) Figure 6
Calibration curve (Response vs. Dose). This curve shows the lineal response of the red, green and blue components 
(RGB mode) as function of the dose. Values are given as means ± SEM.
Table 1: Doses for 2.5 Gy nominal entrance dose measured with HS film and different collimators.
Collimator Diameter (cm) Entrance dose (Gy) Exit dose (Gy) Entrance/Exit
C1 0.5 2.47 ± 0.17 2.01 ± 0.17 1.23
C2 1 2.45 ± 0.15 1.98 ± 0.15 1.24
C3 1.5 2.50 ± 0.14 2.07 ± 0.17 1.21Journal of Experimental & Clinical Cancer Research 2008, 27:57 http://www.jeccr.com/content/27/1/57
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within a depth of about 2 cm [26], and the dose falling off
rapidly into deeper tissues. For example, for X-rays having
HVL = 0.5 cm of Cu (similar to this work), the depth for
50% of maximum dose is about 6 cm [16]. In the context
of small animal tumor models, the small dimensions of
the superficially grown tumor lobes (usually between 1
and 3 centimeters thick), imply that the delivered dose
over the tumor volume will reach values from 80–95% up
to maximum dose [26]. In the present experiment, the
average thickness of the tumors lobes was around 1.5 to
2.0 cm. The results presented in Table 1 have shown that
the differences between the entrance and exit dose were
around 23%, due to attenuation of the X-ray beam in
bone and soft tissues. This result suggests that dose inho-
mogeneities in the tumor reach ± 11.5% around the mean
value which can be estimated as 11.5% lower than the
nominal entrance dose. Within these assumptions, mean
tumor doses in this study were approximately equal to 2.2
Gy, i.e. total dose of 44 Gy after 20 fractions.
Therapeutic response (Relative Tumor Volume vs. Time) for the control and the experimental groups Figure 7
Therapeutic response (Relative Tumor Volume vs. Time) for the control and the experimental groups. Group 
A: cervical cancer xenografts treated with radiotherapy, cisplatin and gemcitabine as explained in the text; Group B: xenografts 
treated with radiotherapy and gemcitabine; Group C: untreated xenografts controls. Arrows indicate beginning and end of the 
treatments. Solid line signals RTV = 1, i.e. no change in tumor volume. Values are given as means ± SEM.
Table 2: Number of cell colonies measured in the clonogenic 
assay.
Group Number of colonies
A1  ±  1
B0  ±  1
C2 0 7  ±  5
Group A: cervical cancer xenografts treated with radiotherapy, 
cisplatin and gemcitabine; Group B: xenografts treated with 
radiotherapy and gemcitabine; Group C: untreated controls.Journal of Experimental & Clinical Cancer Research 2008, 27:57 http://www.jeccr.com/content/27/1/57
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It is well known that inhomogeneous radiation dose dis-
tributions in tumor may result in an incomplete elimina-
tion of tumor cells that may lead to an incomplete
therapeutic response of the treatment, i.e. no reduction or
elimination of the tumoral mass [27]. Same situation is
observed with the inhomogeneous distribution of the
chemotherapy agents in the tumor [28]. In the evaluation
of the synergistic effects of the combination of chemora-
diotherapy treatments in tumor models, one issue to eval-
uate is how homogeneities or inhomogeneities of dose
distributions (radiative and chemotherapeutic) could
affect the therapeutic response of the concomitant treat-
ments; another issue is related with the doses used in both
treatments. The results in this work have shown that a
radiation dose of 2.2 Gy ± 11.5% daily results in an effec-
tive therapeutic response of the experimental groups in
comparison with the control groups (p < 0.05, statistical
power of 1.0 at α = 0.05). This effect could be conse-
quence of the synergism between these treatment modal-
ities, be related to the magnitude of the doses employed
in either modality, or a combination of both. Future
experiments are planned to evaluate and understand these
results.
In this experiment we have used the simplest arrangement
to show the advantages of the method employed with the
orthovoltage X-ray unit. As part of the method evaluation,
we have observed inhomogeneities around the mean
dose. Obviously, an irradiation technique in two opposite
directions should show further improvement in the dose
uniformity, in consequence, it is recommendable the use
of two opposite fields for similar works in cases when the
Evaluation of the loss weight change along time Figure 8
Evaluation of the loss weight change along time. Group A: cervical cancer xenografts treated with radiotherapy, cispla-
tin and gemcitabine; Group B: xenografts treated with radiotherapy and gemcitabine; Group C: untreated controls. Solid line 
signals a relative weight equal to 1, i.e. no change of weight. Values are given as means ± SEM.Journal of Experimental & Clinical Cancer Research 2008, 27:57 http://www.jeccr.com/content/27/1/57
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quoted dose variation across the volume is unacceptable.
The location of the tumor at the lower limbs will help in
this kind of experiments.
When the chemotherapeutic treatments are compared,
results have shown a reduction of the tumor volume as
consequence of the X-ray irradiation with a radiosensitizer
(Group B) or in combination with the chemotherapy
agent (Group A). No difference in the therapeutic
response was observed between these two groups (p >
0.05, statistical power < 0.5 at α = 0.05) in spite of the use
of cisplatin in one of them. A more detailed study should
be performed to analyze and understand this result.
The effectiveness of the chemoradiotherapy treatments,
with the use of the orthovoltage system, was also validated
with the clonogenic assay results, which show that treated
tumoral cells lost their capability to form colonies and
reproduce themselves. Finally, the results have also shown
that the toxicity related with the concurrent chemoradio-
therapy treatment, in terms of the weight loss, was well
tolerated by the nude mice, allowing their recovery two
weeks after the ending of the treatment. It is expected that
the location of the tumor lobe at the mice lower limbs
allows the reduction of radiation toxicity in normal tis-
sues and organs.
Conclusion
The results and procedures described in the present work
have shown the usefulness of the orthovoltage X-ray treat-
ment unit as a small-animal radiation system that allows
the implementation of radiotherapy protocols in combi-
nation with other treatments in animal models.
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